Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HEXA | P06865 | 1/20 | 0.47 |
| ▸ | HEXB | P07686 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813895 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL26101354 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30274282 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30392446 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30392640 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL3892107 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL23720311 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL19541802 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL5371487 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2GAAHPGDNPSR1RAB9A | |
| SCHEMBL30274320 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2GAAHPGDNPSR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | claimed |
| EP-2268609-B1 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD (GB) | 2013-01-30 | — | — | EP | claimed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | claimed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| EP-1594962-A2 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050164974-A1 | Nucleic acid ligand complexes | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20040214258-A1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION | 2004-10-28 | — | — | US | disclosed |
| WO-2004072232-A2 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20030125263-A1 | Nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2003-07-03 | — | — | US | disclosed |
| US-6147204-A | COMPLEX FOR TARGETING THERAPEUTIC OR DIAGNOSTIC AGENTS TO PREFERENTIAL BIOLOGICAL TARGET | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6011020-A | THERAPEUTIC OR DIAGNOSTIC COMPLEX COMPRISED OF A NUCLEIC ACID LIGAND AND A POLYETHYLENE GLYCOL (PEG), WHEREIN SAID NUCLEIC ACID LIGAND IS COVALENTLY LINKED TO SAID PEG | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0824541-A1 | NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996034876-A1 | NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-20050164974-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | SMN1; SMN2 1911/4885GAA 1663/4885HPGD 4637/4885 |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GAS6, LNPEP, BMP6 | SMN1; SMN2 4557/4885GAA 472/4885HPGD 2639/4885 |
| US-20030125263-A1 | Nucleic acid ligand complexes | TLR9, SNRPE, HAVCR2 | SMN1; SMN2 1911/4885GAA 1663/4885HPGD 4637/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885GAA 1234/4885HPGD 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.